David Clark
Showing 1–3 of 3 transcripts.
- a16z33 min
The New Rule for Picking AI Winners | The a16z Show
Frontier AI firms like Anthropic and OpenAI are currently outpacing the combined revenue growth of major tech giants, with a projected collective run rate of $200 billion driving valuations toward $100 billion by September. While current enterprise adoption remains largely efficiency-focused, supply chain constraints are expected to persist until late 2028, preventing an oversupply bubble despite the rapid scaling of $5 trillion in data center capital expenditures. As venture strategies pivot to securing market leaders in a shrinking startup half-life, the industry is poised for a structural shift where dominant AI entities redefine public market dynamics and consumer engagement over the next decade.
David Clark: Lessons from 32 Years of Fund Investing - Why Exits Will Be Larger | E1131
David Clark, Harry Stebbings, Doug Leone, Ryan Akinna
A longitudinal analysis of 1,200 funds reveals that while only 2.6% achieve 5x net DPI, a specific investment firm has maintained a loss rate under 3% by rigorously selecting a core group of top-tier managers during low-noise cycles. This strategy prioritizes identifying the 1% of managers capable of accessing power-law outcomes, utilizing a 100% outbound sourcing model that focuses on Fund 3 launches and enforces three-year deployment periods to mitigate timing risks. Operating with a blended return of 3x to 3.5x across mature funds, the firm continues to navigate market volatility by avoiding overpaying in inflated cycles and adapting to a shifting landscape where late-stage investing faces commoditization while early-stage craft remains essential.
- a16z13 min
On Machine Learning in Medicine and More
Andreessen Horowitz is distinguishing its bio-investing strategy by applying software methodologies and machine learning to traditional biological challenges, specifically targeting digital therapeutics, computational medicine, and cloud biology infrastructure. This approach leverages hybrid founders with dual expertise in computer science and biology to de-risk drug development, enabling scalable solutions that integrate with existing healthcare systems while projecting software-like returns. By transforming healthcare from acute intervention to preventative maintenance through advanced data analytics, the firm aims to secure exit multiples significantly higher than those typical of conventional life sciences ventures.